Levormeloxifene

Levormeloxifene is a selective [estrogen receptor modulator] which was being developed as an alternative to hormone [replacement therapy (menopause)|estrogen replacement therapy] for the treatment and prevention of postmenopausal bone loss but did not complete development and hence was never marketed. The development was stopped because of a high incidence of gynecological side effects during clinical trials. Levormeloxifene is the levorotatory enantiomer of ormeloxifene, which, in contrast, has been marketed, though rather as a hormonal contraceptive.